NCT06067841RecruitingPhase 1
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 28 Sept 2023
- Start date
- 18 Oct 2023
- Primary completion date
- 24 Aug 2029
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Prostate cancer
- NCT number
- NCT06067841
- EU CT number
- 2024-513987-24-00
- EudraCT number
- 2024-513987-24
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 140
- From 18 Oct 2023 to the primary completion date, 24 Aug 2029
- 15 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participant must not have history of brain metastases.
- Participant must not have impaired cardiac function or clinically significant cardiac disease.
Lab values
- Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.
- Other protocol-defined inclusion/exclusion criteria apply
Who the study is looking for
- Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
- Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
- Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Montreal | Canada | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Not yet recruiting |
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| Assistance Publique Hopitaux de Paris Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Duke Cancer Institute Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Stanford Cancer Center Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Withdrawn |
| NEXT Oncology Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
| Florida Cancer Specialists Sarasota Drug Development Unit Coordinator of this site? Confirm its status | Sarasota | United States | Recruiting |
| Fred Hutchinson Cancer Center Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.